FDA approves Allergan’s Rhofade cream

SILVER SPRING, Md. — The Food and Drug Administration has approved Allergan’s Rhofade (oxymetazoline hydrochloride) cream, the company announced Thursday. The cream is indicated to treat persistent facial redness from rosacea in adults. 

 

"The FDA approval of Rhofade exemplifies Allergan's commitment to continuing to address unmet patient needs through innovation in medical dermatology,” Allergan chief R&D officer David Nicholson said. "The FDA approval of Rhofade represents a new prescription treatment that can effectively help physicians and their patients manage this condition."   

 

The National Rosacea Society estimates that some 16 million Americans are affected by rosacea. The company expects the drug to be available for commercial supply in May.